At Glenmark Pharmaceuticals, research and innovation are the cornerstones of our business. We advance leading-edge science through a dynamic and collaborative approach. This enables us to find better solutions for treating the world’s most challenging diseases. Expanding on Glenmark’s first biologics discovery centre, founded in La Chaux-de-Fonds in 2006, our newest discovery centre Glenmark BioTherapeutics, in the Biopôle was opened in 2018. The new centre provides the resources and facilities for scientists to perform cutting-edge research in antibody and protein discovery and engineering, in vivo pharmacology, target generation and scale-up, all alongside ongoing translational studies of our potential first- and best-in-class biologic candidates.
Glenmark’s translational biologics research focuses on the discovery and development of new biological entities (NBEs) primarily in the areas of Immunology and Oncology. Operations include end-to-end capabilities to discover NBEs and development from inception through preclinical studies. Our team conducts the scientific investigation to support the clinical development of our candidates, translating basic research into potential new therapies that will benefit patients. Glenmark’s robust pipeline currently includes five biologics and a biosimilar in various stages of development.